BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31854124)

  • 21. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Pike E; Grafinger KE; Cannaert A; Ametovski A; Luo JL; Sparkes E; Cairns EA; Ellison R; Gerona R; Stove CP; Auwärter V; Banister SD
    Drug Test Anal; 2021 Jul; 13(7):1383-1401. PubMed ID: 33787091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists.
    Patel M; Finlay DB; Glass M
    Cell Signal; 2021 Feb; 78():109865. PubMed ID: 33259937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.
    Glatfelter GC; Partilla JS; Baumann MH
    Neuropsychopharmacology; 2022 Mar; 47(4):924-932. PubMed ID: 34802041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
    Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
    Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
    Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
    Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
    Banister SD; Moir M; Stuart J; Kevin RC; Wood KE; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Glass M; Connor M; McGregor IS; Kassiou M
    ACS Chem Neurosci; 2015 Sep; 6(9):1546-59. PubMed ID: 26134475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market.
    Norman C; Walker G; McKirdy B; McDonald C; Fletcher D; Antonides LH; Sutcliffe OB; Nic Daéid N; McKenzie C
    Drug Test Anal; 2020 Apr; 12(4):538-554. PubMed ID: 31944624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons.
    Norman C; McKirdy B; Walker G; Dugard P; NicDaéid N; McKenzie C
    Drug Test Anal; 2021 Mar; 13(3):644-663. PubMed ID: 33058556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
    Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
    Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
    Lea Houston M; Morgan J; Kelso C
    Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine.
    Wouters E; Mogler L; Cannaert A; Auwärter V; Stove C
    Drug Test Anal; 2019 Aug; 11(8):1183-1191. PubMed ID: 31021521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
    Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
    Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification.
    Hill SL; Dunn M; Cano C; Harnor SJ; Hardcastle IR; Grundlingh J; Dargan PI; Wood DM; Tucker S; Bartram T; Thomas SHL
    Clin Chem; 2018 Feb; 64(2):346-354. PubMed ID: 29038156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB
    Patel M; Grimsey NL; Banister SD; Finlay DB; Glass M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01157. PubMed ID: 38018694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
    Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
    Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
    J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
    Chung EY; Cha HJ; Min HK; Yun J
    Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.
    Waugh J; Najafi J; Hawkins L; Hill SL; Eddleston M; Vale JA; Thompson JP; Thomas SH
    Clin Toxicol (Phila); 2016 Jul; 54(6):512-8. PubMed ID: 27091041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.